scholarly journals Genomic profiling of the UFMylation family genes identifies UFSP2 as a potential tumour suppressor in colon cancer

2021 ◽  
Vol 11 (12) ◽  
Author(s):  
Junzhi Zhou ◽  
Xiaohe Ma ◽  
Lu Xu ◽  
Qian Liang ◽  
Jian Mao ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Tumour Suppressor ◽  
Genomic Profiling

scholarly journals Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer

2006 ◽  
Vol 95 (10) ◽  
pp. 1419-1423 ◽  
Author(s):  
C Rimkus ◽  
M Martini ◽  
J Friederichs ◽  
R Rosenberg ◽  
D Doll ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Significance ◽  
Suppressor Gene ◽  
Tumour Suppressor Gene ◽  
Tumour Suppressor ◽  
Candidate Tumour Suppressor

Comprehensive genomic profiling of ctDNA in patients with colon cancer and its fidelity to the genomics of the tumor biopsy.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 569-569 ◽  
Author(s):  
Jeffrey P. Gregg ◽  
Gerald Li ◽  
Dean Pavlick ◽  
Jon Chung ◽  
Matthew Cooke ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Stage Iv ◽  
Prospective Clinical Study ◽  
Genomic Profiling ◽  
Blood Draw ◽  
Tumor Biopsy ◽  
Comprehensive Genomic Profiling ◽  
Tumor Types ◽  
Ct Dna ◽  
Clinical Trial Information

569 Background: The liquid biopsy offers the ability to non-invasively analyze the genome of a tumor through circulating tumor (ct) DNA to identify targetable and prognostic genomic alterations. Few studies have rigorously analyzed ctDNA results and determined the fidelity with which they recapitulate the genomics of the tumor. The clinical utility study (CUS) for FoundationACT (Foundation Medicine, Cambridge, MA; NCT02620527) is a large multi-center prospective clinical study to validate this ctDNA assay for multiple solid tumor types. In this subset of the CUS study, paired specimens from 98 patients with colon cancer were analyzed with comprehensive genomic profiling of the tumor (FoundationOne) and a blood sample (FoundationACT). Methods: Maximum somatic allele fraction (MSAF) was used to estimate the fraction of ctDNA in the sample. The set of genes and targeted regions common to both FoundationOne and FoundationACT were compared for each subject. Results: 60% were male; 73 had stage IV, 17 had stage III, and 8 had stage II disease. 16% of cases had an MSAF value of 0, indicating that no ctDNA were in these samples. For the cases with MSAF > 0, 153 insertion/deletions (indels)/substitutions were identified in the tumor, and 73% of these identical alterations were also identified in the ctDNA samples. As robust analytical performance for FoundationACT has been demonstrated at MSAF > 0.5% for indel/subs, further analysis was conducted using this threshold. 83% of the alterations identified with FoundationOne were identified with FoundationACT. Further, 90% of NRAS/KRAS and 75% BRAF alterations (NCCN guideline genes) were concordant between the two assays. Lastly, there were 11 patients with tumor biopsy and blood draw taken within 30 days of each other, and in these there was 100% concordant. Association of the genomics results with other clinical variables will be presented for the available subset of patients. Conclusions: In cases where tumor profiling is not possible, these results provide compelling evidence that comprehensive molecular profiling of ctDNA in colon cancer can be used to identify most clinically relevant alterations and has fidelity to the genomics of the tumor. Clinical trial information: NCT02620527.

scholarly journals TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway

Oncogene ◽  
2014 ◽  
Vol 34 (32) ◽  
pp. 4168-4176 ◽  
Author(s):  
F Neri ◽  
D Dettori ◽  
D Incarnato ◽  
A Krepelova ◽  
S Rapelli ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Wnt Pathway ◽  
Tumour Suppressor ◽  
Cancer Growth

scholarly journals Vitamin C promotes decitabine or azacytidine induced DNA hydroxymethylation and subsequent reactivation of the epigenetically silenced tumour suppressor CDKN1A in colon cancer cells

Oncotarget ◽  
2018 ◽  
Vol 9 (67) ◽  
pp. 32822-32840 ◽  
Author(s):  
Christian Gerecke ◽  
Fabian Schumacher ◽  
Alexander Edlich ◽  
Alexandra Wetzel ◽  
Guy Yealland ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Vitamin C ◽  
Cancer Cells ◽  
Tumour Suppressor ◽  
Colon Cancer Cells ◽  
Dna Hydroxymethylation

Utility of tumor genomic profiling in guiding targeted therapy and referral for clinical trials in the community practice.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18381-e18381
Author(s):  
Yiqing Xu ◽  
Jiang Yio ◽  
Amber Yang ◽  
Ashrei Bayewitz ◽  
Daniel Benasher ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Colon Cancer ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Driver Mutations ◽  
Cancer Type ◽  
Tumor Type ◽  
Genomic Profiling ◽  
Community Practice ◽  
Match Trial

e18381 Background: Next-generation sequencing (NGS), which enables tumor genomic profiling with limited tumor specimen for the guidance of targeted therapy, has been widely used in oncology practice. It also reports mutations of which no approved therapy is available, but potential therapies approved in a different tumor type may be reasonable to try, based on molecular mechanisms or limited data, either in clinical trials or off trial treatment. The utility of this information in the community practice is unclear. Methods: We performed a retrospective analysis on the usage of NGS result on patients with lung or colorectal cancers treated between November 2011 and February 2018. Patients were identified from Foundation Medicine Company database and were linked to records at Maimonides. We evaluated if NGS was used to guide FDA-approved targeted therapy, potentially-useful targeted therapy not approved for the cancer type, or referral to a clinical trial. Results: 177 patients (lung ca = 119, colon ca = 58) were included. NGS identified 34 (28.6%) lung ca patients with driver mutations, (21 EGFR, 6 RET, 3 ALK, 2 MET amplification, 1 ROS1 and 1NTRK mutation), who were all given FDA-approved therapy. 70 (58.8%) patients had at least 1 target with an FDA-approved therapy for a different cancer; 89 (74.9%) had a mutation being studied in a clinical trial, and 48 patients were eligible for the NCI-MATCH trial. None received non-FDA-approved drugs and none was referred to clinical trials. In the colon cancer cohort, NGS identified alterations in KRAS (27), BRAF (5), ERBB2 mutation (2), ERBB2 amplification (1), MLH1 (1), MSH2 (1) and BRCA 2(1). Among them, one patient received BRAF inhibitors. 45 and 24 patients were eligible for phase I/II trials and NCI-MATCH trial respectively, and none was referred. Conclusions: NGS has a high efficiency of detecting driver mutations in lung cancer; but only reveals low frequencies of alterations otherwise not tested in colon cancer. The approach of prescribing un-approved targeted treatment based on theoretical mechanism of action was very uncommon, and the referral to clinical trials was rare in this community practice, both of which decreasing the utility value of NGS.

Alterations in tumour suppressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells

1998 ◽  
Vol 433 (5) ◽  
pp. 415-418 ◽  
Author(s):  
Tetsuji Tokunaga ◽  
M. Nakamura ◽  
Yoshiro Oshika ◽  
Takashi Tsuchida ◽  
Michitake Kazuno ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colon Cancer ◽  
Cancer Cells ◽  
Suppressor Gene ◽  
Tumour Suppressor Gene ◽  
Tumour Suppressor ◽  
Colon Cancer Cells ◽  
Thrombospondin 1

scholarly journals Mindin serves as a tumour suppressor gene during colon cancer progression through MAPK/ERK signalling pathway in mice

2020 ◽  
Vol 24 (15) ◽  
pp. 8391-8404
Author(s):  
Xiao‐Shen Cheng ◽  
Ya‐Ni Huo ◽  
Yan‐Yun Fan ◽  
Chuan‐Xing Xiao ◽  
Xiao‐Mei Ouyang ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Progression ◽  
Suppressor Gene ◽  
Tumour Suppressor Gene ◽  
Tumour Suppressor ◽  
Signalling Pathway ◽  
Colon Cancer Progression

scholarly journals The tumour suppressor effects and regulation of cancer stem cells by macrophage migration inhibitory factor targeted miR-451 in colon cancer

Gene ◽  
2019 ◽  
Vol 697 ◽  
pp. 165-174 ◽  
Author(s):  
Afraa Mamoori ◽  
Riajul Wahab ◽  
Jelena Vider ◽  
Vinod Gopalan ◽  
Alfred King-yin Lam
Keyword(s):  
Stem Cells ◽  
Colon Cancer ◽  
Cancer Stem Cells ◽  
Migration Inhibitory Factor ◽  
Macrophage Migration Inhibitory Factor ◽  
Tumour Suppressor ◽  
Inhibitory Factor ◽  
Macrophage Migration
Sign in / Sign up

Export Citation Format

Share Document